Factores asociados a infecciones en pacientes con artritis reumatoide tratados con abatacept subcutáneo atendidos en un centro de reumatología en Bogotá, Colombia

dc.contributorMolano-González, Nicolas
dc.creatorGómez Cárdenas, Oscar Eduardo
dc.date.accessioned2017-05-08T14:23:06Z
dc.date.available2017-05-08T14:23:06Z
dc.date.created2017-05-08T14:23:06Z
dc.date.issued2017
dc.identifierhttp://repository.urosario.edu.co/handle/10336/13350
dc.identifierhttps://doi.org/10.48713/10336_13350
dc.description.abstractINTRODUCTION: The aim of treatment for rheumatoid arthritis is to decrease the activity of the disease by modulating the immune system, with infections being one of the common adverse effects. Abatacept has immunomodulatory effect by inhibiting the co-stimulation of T lymphocytes reducing the inflammatory activity. OBJECTIVE: To determine the factors associated with the presentation of infections in patients with rheumatoid arthritis treated with subcutaneous abatacept. METHODS: Cross-sectional analytical study. The sociodemographic clinical and paraclinical characteristics of the patients were established. Statistical analysis determined those that were related to the presentation of infections. RESULTS: We included 59 (83. 09%) women and 12 (16. 90%) men with a mean age of 50. 92 years (SD 13. 50). 47 (66. 19%) had at least 1 infection report. Having received more than one antiTNF is associated with a lower number of reports per patient (p = 0. 046). The relationship between the number of previous antiTNFs and the presentation of infections (p = 0. 047) and the number of reported events (p = 0. 011) is independent of the sex and age of the patient. During the first 5 months of treatment there is a greater likelihood of recurrent infections (Spearman = -0. 42). CONCLUSIONS: Before initiating treatment with abatacept, history of previous treatment with antiTNF for rheumatoid arthritis should be considered, a close follow-up should be considered during the first 5 months. It’s necessary to carry out population studies with probabilistic sampling that explore factors that allow the construction of risk profiles for infections.
dc.languagespa
dc.publisherUniversidad del Rosario
dc.publisherFacultad de medicina
dc.rightshttp://creativecommons.org/licenses/by-sa/2.5/co/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAbierto (Texto completo)
dc.rightsAtribución-CompartirIgual 2.5 Colombia
dc.rightsEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.
dc.sourceScott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet. 2010;376(9746):1094–108.
dc.sourceNandakumar KS. Pathogenic antibody recognition of cartilage. Cell Tissue Res. 2010;339(1):213–20.
dc.sourceSmolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2013 update. Ann Rheum Dis. 2013;1–18.
dc.sourceSingh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016;68(1):1–25.
dc.sourceTanaka Y. Current concepts in the management of rheumatoid arthritis. Korean J Intern Med. el 1 de marzo de 2016;31(2):210–8.
dc.sourceSingh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: A systematic review and meta-analysis. Lancet. 2015;386(9990):258–65.
dc.sourceGalloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emph. Rheumatology. 2010;50(1):124–31.
dc.sourceReilly PA, Cosh JA, Maddison PJ, Rasker JJ, Silman AJ. Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients. Ann Rheum Dis. 1990;49(6):363–9.
dc.sourceCaporali R, Caprioli M, Bobbio-Pallavicini F, Montecucco C. DMARDS and infections in rheumatoid arthritis. Autoimmun Rev. 2008;8(2):139–43.
dc.sourceCrowson C, Hoganson D, Fitz-Gibbon P. Development and validation of a risk score for serious infection in patients with rheumatoid arthritis. Arthritis Rheum. 2012;64(9):2847–55.
dc.sourceCurtis JR, Xie F, Chen L, Muntner P, Grijalva CG, Spettell C, et al. Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high-versus lower-risk rheumatoid arthritis patients. Arthritis Care Res. 2012;64(10):1480–9.
dc.sourceAlamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev. 2005;4(3):130–6.
dc.sourceDíaz-rojas JA, Dávila-ramírez FA, Quintana-lópez G, Aristizábal-gutiérrez F. Prevalencia de artritis reumatoide en Colombia : una aproximación basada en la carga de la enfermedad durante el a ño 2005. Rev Colomb Reumatol. 2016;3(1):11–6.
dc.sourceAnaya J-M. The autoimmune tautology. Arthritis Res Ther. 2010;12(6):147.
dc.sourceLing S, Cline EN, Haug TS, Fox DA, Holoshitz J. Citrullinated calreticulin potentiates rheumatoid arthritis shared epitope signaling. Arthritis Rheum. marzo de 2013;65(3):618–26.
dc.sourceLee YH, Bae SC, Song GG. Gene-environmental interaction between smoking and shared epitope on the development of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: A meta-analysis. Int J Rheum Dis. febrero de 2014;17(5):528–35.
dc.sourceTerao C, Yano K, Ikari K, Furu M, Yamakawa N, Yoshida S, et al. Brief Report: Main Contribution of DRB1*04:05 Among the Shared Epitope Alleles and Involvement of DRB1 Amino Acid Position 57 in Association With Joint Destruction in Anti-Citrullinated Protein Antibody-Positive Rheumatoid Arthritis. Arthritis Rheumatol (Hoboken, NJ). julio de 2015;67(7):1744–50.
dc.sourceWestergaard MW, Draborg AH, Troelsen L, Jacobsen S, Houen G. Isotypes of Epstein-Barr Virus Antibodies in Rheumatoid Arthritis: Association with Rheumatoid Factors and Citrulline-Dependent Antibodies. Biomed Res Int. 2015;2015:1–9.
dc.sourceUhlig T, Loge JH, Kristiansen IS KT. Quantification of reduced health-related quality of life in patients with rheumatoid arthritis compared to the general population. J Rheumatol. 2007;34(6):1241–1247 7p.
dc.sourceVilagut G, Ferrer M, Rajmil L, Rebollo P, Permanyer-Miralda G, Quintana JM, et al. El Cuestionario de Salud SF-36 español: una década de experiencia y nuevos desarrollos. Gac Sanit. 2005;19(2):135–50.
dc.sourceMatcham F, Scott IC, Rayner L, Hotopf M, Kingsley GH, Norton S, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: A systematic review and meta-analysis. Semin Arthritis Rheum. 2015;44(2):123–30.
dc.sourceNaz SM, Symmons DPM. Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007;21(5):871–83.
dc.sourceSymmons DPM, Jones MA, Scott DL, Prior P. Longterm mortality outcome in patients with rheumatoid arthritis: Early presenters continue to do well. J Rheumatol. 1998;25(6):1072–7.
dc.sourceMontoya N, Gómez L, Vélez M, Rosselli D. Costos directos del tratamiento de pacientes con artritis reumatoide en Medellín, Colombia. Rev Colomb Reumatol. 2011;18:26–33.
dc.sourceWasserman.A. Diagnosis and Management of Rheumatoid Arthritis. Am Fam Physician. 2011;84(11):1245–52.
dc.sourceShamim R, Jan MD, Zafar U. Prevalence of rheumatoid arthritis in population with arthralgia presenting to a tertiary care hospital. J Pak Med Assoc. 2015;65(11):1202–5.
dc.sourceMinisterio de Salud y Protección Social. Guía de Práctica Clínica (GPC) para la detección temprana, diagnóstico y tratamiento de la artritis reumatoide. 2014.
dc.sourceArnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS H LA, Kaplan SR, Liang MH, Luthra HS et al. The American Rheumatism Association 1987 Revised Criteria for the Classification of Rheumatoid Arthritis. Arthritis Rheum. 1988;31(3):315–24.
dc.sourceSingh JA, Solomon DH, Dougados M, Felson D, Hawker G, Katz P, et al. Development of classification and response criteria for rheumatic diseases. Arthritis Care Res. 2006;55(3):348–52.
dc.sourceAletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81.
dc.sourceGómez A. Nuevos criterios de clasificación de artritis reumatoide. Reumatol Clin. 2010;6(SUPPL. 3):33–7.
dc.sourceAnderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken). 2012;64(5):640–7.
dc.sourceWells G, Becker J-C, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. el 1 de junio de 2009;68(6):954–60.
dc.sourceWolfe F, Michaud K, Pincus T. Development and validation of the Health Assessment Questionnaire II: A revised version of the Health Assessment Questionnaire. Arthritis Rheum. 2004;50(10):3296–305.
dc.sourceSmyrnova G. Relação entre o nível de hemoglobina e a atividade da doença em pacientes com artrite reumatoide. Rev Bras Reumatol. noviembre de 2014;54(6):437–40.
dc.sourceRaczkiewicz A, Kisiel B, Kulig M, Tłustochowicz W. Vitamin D Status and Its Association With Quality of Life, Physical Activity, and Disease Activity in Rheumatoid Arthritis Patients. JCR J Clin Rheumatol. abril de 2015;21(3):126–30.
dc.sourceSandberg MEC, Bengtsson C, Källberg H, Wesley A, Klareskog L, Alfredsson L, et al. Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis. Ann Rheum Dis. noviembre de 2014;73(11):2029–33.
dc.sourceFautrel B, den Broeder AA. De-intensifying treatment in established rheumatoid arthritis (RA): Why, how, when and in whom can DMARDs be tapered? Best Pract Res Clin Rheumatol. agosto de 2015;29(4–5):550–65.
dc.sourceWoodworth TG, den Broeder AA. Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilars. Best Pract Res Clin Rheumatol. agosto de 2015;29(4–5):543–9.
dc.sourceKaine JL. Abatacept for the treatment of rheumatoid arthritis: A review. Curr Ther Res - Clin Exp. 2007;68(6):379–99.
dc.sourceSchiff M. Subcutaneous abatacept for the treatment of rheumatoid arthritis. Rheumatol (United Kingdom). 2013;52(6):986–97.
dc.sourceKremer JM, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Westhovens R, et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis. 2011;70(10):1826–30.
dc.sourceRozelle AL, Genovese MC. Efficacy results from pivotal clinical trials with abatacept. Clin Exp Rheumatol. 2007;25(5 SUPPL. 46).
dc.sourceSchiff M, Pritchard C, Huffstutter JE, Rodriguez-Valverde V, Durez P, Zhou X, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis. 2009;68(11):1708–14.
dc.sourceAlten R, Kaine J, Keystone E, Nash P, Delaet I, Genovese MC. Long-term safety of subcutaneous abatacept in rheumatoid arthritis: Integrated analysis of clinical trial data representing more than four years of treatment. Arthritis Rheumatol. 2014;66(8):1987–97.
dc.sourceDoran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: A population-based study. Arthritis Rheum. 2002;46(9):2287–93.
dc.sourceReumatología RC De, Reumatología C De. Complicaciones infecciosas en la artritis reumatoide durante una década en el Centro de Reumatología. 2014;276–82.
dc.sourceDoran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46(9):2294–300.
dc.sourceMiranda JV, Pinto Peñaranda LF, Muñoz Grajales C, Márquez Hernández JD, Rodríguez Padilla LM, Velásquez Franco CJ. Infecciones en pacientes con artritis reumatoide: medicamentos moduladores de la respuesta biológica versus fármacos modificadores de la enfermedad. Seguimiento a un año. Rev Colomb Reumatol. 2014;21(1):27–34.
dc.sourceLahaye C, Soubrier M, Mulliez A, Bardin T, Cantagrel A, Combe B, et al. Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology’s ORA registry. Rheumatology (Oxford). 2016;55(5):874–82.
dc.sourceStrangfeld A, Zink A. Sicherheit unter Biologika – Ergebnisse aus dem deutschen Biologika-Register RABBIT. DMW - Dtsch Medizinische Wochenschrift. el 2 de septiembre de 2014;139(37):1817–20.
dc.sourceWood SN. Generalized additive models. An introduction with R. 1a ed. Chapman and Hall, CRC press; 2006.
dc.sourceMcCullagh, Nelder. Generalized lineal models. 2a ed. Chapman and Hall; 1989.
dc.sourceCastiblanco J, Sarmiento-Monroy JC, Mantilla RD, Rojas-Villarraga A, Anaya J-M. Familial Aggregation and Segregation Analysis in Families Presenting Autoimmunity, Polyautoimmunity, and Multiple Autoimmune Syndrome. J Immunol Res. 2015;2015:1–10.
dc.sourceSalmon JH, Gottenberg JE, Ravaud P, Cantagrel A, Combe B, Flipo RM, et al. Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry. Ann Rheum Dis. 2015;0:1–6.
dc.sourceGong IY, Kim RB. Impact of genetic variation in OATP transporters to drug disposition and response. Drug Metab Pharmacokinet. 2013;28(1):4–18.
dc.sourceStrangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis. 2011;70(11):1914–20.
dc.sourceFlouri I, Repa A, Fanouriakis A, Kougkas N, Papalopoulos I, Kampouraki E, Boumpas D, Avgoustidis N, Bertsias G SP. Abatacept-Treated Rheumatoid Arthritis Patients Have Better Drug-Survival Rate When Abatacept Is the First or Second Line Biologic Agent with an Excellent Overall Safety Profile: A Single Center Experience [abstract]. Arthritis Rheumatol. 2015;67(suppl 10).
dc.sourceinstname:Universidad del Rosario
dc.sourcereponame:Repositorio Institucional EdocUR
dc.subjectAntirreumáticos
dc.subjectInmunomoduladores
dc.subjectCTLA-4
dc.subjectAutoinmunidad
dc.subjectBiológicos
dc.titleFactores asociados a infecciones en pacientes con artritis reumatoide tratados con abatacept subcutáneo atendidos en un centro de reumatología en Bogotá, Colombia
dc.typebachelorThesis


Este ítem pertenece a la siguiente institución